Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
Background Programmed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developing immune-related adverse events (irAE). Delineati...
Saved in:
| Main Authors: | Peng Yang, Wendy Blumenschein, David Bauché, Smita Mauze, Christina Kochel, Jeff Grein, Anandi Sawant, Yulia Zybina, Lakshmanan Annamalai, Jennifer H Yearley, Juha Punnonen, Edward P Bowman, Alissa Chackerian, Drake Laface |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001584.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer
by: Thai Q. Tran, et al.
Published: (2024-06-01) -
Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
by: Kuang Youlin, et al.
Published: (2012-01-01) -
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01) -
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01) -
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
by: Michal Lotem, et al.
Published: (2016-01-01)